Armata Pharmaceuticals Inc (ARMP)
2.50
+0.01
(+0.40%)
USD |
NYAM |
May 03, 10:17
Armata Pharmaceuticals Enterprise Value: 158.79M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 02, 2024 | 158.79M |
May 01, 2024 | 155.54M |
April 30, 2024 | 160.96M |
April 29, 2024 | 162.77M |
April 26, 2024 | 168.55M |
April 25, 2024 | 160.26M |
April 24, 2024 | 159.15M |
April 23, 2024 | 160.23M |
April 22, 2024 | 159.51M |
April 19, 2024 | 165.11M |
April 18, 2024 | 160.96M |
April 17, 2024 | 159.15M |
April 16, 2024 | 184.45M |
April 15, 2024 | 185.54M |
April 12, 2024 | 186.26M |
April 11, 2024 | 188.43M |
April 10, 2024 | 191.68M |
April 09, 2024 | 199.27M |
April 08, 2024 | 199.27M |
April 05, 2024 | 205.42M |
April 04, 2024 | 203.25M |
April 03, 2024 | 200.72M |
April 02, 2024 | 201.08M |
April 01, 2024 | 209.76M |
March 28, 2024 | 219.88M |
Date | Value |
---|---|
March 27, 2024 | 216.99M |
March 26, 2024 | 214.82M |
March 25, 2024 | 210.12M |
March 22, 2024 | 203.97M |
March 21, 2024 | 202.16M |
March 20, 2024 | 196.75M |
March 19, 2024 | 205.43M |
March 18, 2024 | 193.13M |
March 15, 2024 | 198.92M |
March 14, 2024 | 190.88M |
March 13, 2024 | 193.41M |
March 12, 2024 | 200.63M |
March 11, 2024 | 190.88M |
March 08, 2024 | 197.02M |
March 07, 2024 | 197.02M |
March 06, 2024 | 202.80M |
March 05, 2024 | 204.97M |
March 04, 2024 | 217.61M |
March 01, 2024 | 215.80M |
February 29, 2024 | 211.11M |
February 28, 2024 | 208.94M |
February 27, 2024 | 196.30M |
February 26, 2024 | 176.79M |
February 23, 2024 | 177.15M |
February 22, 2024 | 173.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.577M
Minimum
May 03 2019
219.88M
Maximum
Mar 28 2024
82.64M
Average
77.70M
Median
Jul 14 2021
Enterprise Value Benchmarks
AIM ImmunoTech Inc | 7.789M |
Perspective Therapeutics Inc | 1.008B |
Protalix BioTherapeutics Inc | 60.43M |
Electromed Inc | 142.82M |
Xtant Medical Holdings Inc | 128.57M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -19.85M |
Total Expenses (Quarterly) | 9.579M |
EPS Diluted (Quarterly) | -0.55 |
Earnings Yield | -79.20% |
Normalized Earnings Yield | -1685.65 |